NCT01420991

Brief Summary

Aneurysmal subarachnoid hemorrhage (aSAH) is the most deadly kind of stroke. Each year, 40,000 Americans have SAH. Case-fatality approaches 60% and more than half of those who die do so before reaching the hospital. Most commonly, SAH results from rupture of an intracranial aneurysm. Screening high-risk individuals could identify those at greatest risk and decrease the devastating effect of SAH. Aortic Aneurysm also constitutes a major public health problem with high lethality. Current estimates are that ruptured aortic aneurysm kills 13,000 Americans each year. Screening efforts have effectively lowered mortality from aortic aneurysm rupture but a high proportion of those who die did not have a diagnosis of aortic aneurysm prior to rupture. The relationship between intracranial and aortic aneurysm has long been recognized, but poorly quantified. Recent genome-wide association studies (GWAS) provide a molecular biological evidence for a shared pathophysiology. The chromosome 9p21 locus confers increased risk for both intracranial aneurysms and aortic aneurysms. These GWAS data, along with linkage data for other susceptibility loci, indicate that individuals and families harboring one type of aneurysm may be at especially increased risk of the other. The rationale for this project is that opportunistic screening for abdominal aortic aneurysms (AAA) may be warranted in patients who present with aneurysmal subarachnoid hemorrhage. This study is meant to see if the yield of screening in this population is too low to justify its routine use. The investigators plan to systematically screen for AAA in all cases of aSAH presenting to MCH for treatment. If no individual out of 81 consecutively screened cases of aSAH has evidence of AAA, then the investigators can have strong confidence that there is a less than 5% chance of finding an AAA in the patient population.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
271

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2021

Typical duration for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 15, 2011

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 22, 2011

Completed
10.1 years until next milestone

Study Start

First participant enrolled

October 11, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 2, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 2, 2024

Completed
Last Updated

April 16, 2025

Status Verified

March 1, 2025

Enrollment Period

2.4 years

First QC Date

August 15, 2011

Last Update Submit

April 15, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Prevalence

    The primary aim is to determine the proportion of patients who are found to have an AAA at the time of enrollment.

    day 1

Secondary Outcomes (1)

  • Assessment of functional outcomes at 30 days

    30days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

We will enroll 81 patients who present to MCH with aSAH.

1. Men and women age ≥ 18 years. 2. Diagnosis of intracranial aneurysm secured by magnetic resonance angiography (MRA), computed tomographic angiography (CTA), or catheter-based cerebral angiography. 3. Diagnosis of subarachnoid hemorrhage diagnosed by head CT, brain MRI or lumbar puncture. 4. Provides written informed consent. 5. No know diagnosis of aortic aneurysm 6. No history of prior screening for aortic aneurysm 7. No condition like recent abdominal surgical scar that would preclude abdominal ultrasonography 8. No therapy like abdominal hypothermia pads that would preclude abdominal ultrasonography

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (2)

Mayo Clinic in Florida

Jacksonville, Florida, 32224, United States

Location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Conditions

Aneurysm

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • James Meschia, MD

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

August 15, 2011

First Posted

August 22, 2011

Study Start

October 11, 2021

Primary Completion

March 2, 2024

Study Completion

March 2, 2024

Last Updated

April 16, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations